Researchers found that high-dose VE303 prevented recurrent C. difficile infection compared to placebo, suggesting a potential new treatment approach. A larger phase 3 study is needed to confirm these findings.
Denmark has seen a significant surge in strep A infections, particularly among the elderly, since late 2022. The new M1 subvariant is responsible for 30% of cases and may be contributing to the outbreak's severity.
Researchers at Shinshu University developed a microfluidic device using acoustic focusing to collect microplastics from water. The device achieved a 105-fold enrichment of MPs, making it an efficient solution for removing microplastics from laundry and industrial wastewater.
Researchers found that remnants of ancient retroviruses in the human genome can be targeted by antibodies to improve lung cancer treatment. The study suggests that boosting antibody responses could help predict patient response to immunotherapy and lead to improved outcomes.
The European Society of Cardiology has published a detailed guidance on the natural pacemaker method, which mimics the heart's normal function. This method can benefit approximately half of the 1.4 million patients who will receive a pacemaker in 2023, particularly those with atrioventricular block or left bundle branch block.
Infections caused by Group A Streptococcus (GAS) decreased by 80% as COVID-19 lockdown took effect and remained low until March 2022, when they increased 18% a month to surpass pre-COVID levels.
A major UK study has discovered that disturbed sleep patterns in patients hospitalised with COVID-19 were likely a driver of breathlessness. The study found that 62% of participants experienced sleep disruption, which persisted for at least 12 months and was associated with anxiety and muscle weakness.
The highest incidence of invasive Group A Streptococcus (GAS) disease has shifted from the most deprived groups to the second most affluent group in the UK, according to new research. The emm1 strain, which causes severe disease, was more common in 2022 than previous years.
Researchers identified protective drugs that shield two abundant gut bacterial species without compromising antibiotic effectiveness against disease-causing bacteria. The study found a novel combination of antibiotics with antidote drugs, such as dicumarol and tolfenamic acid, which protected the gut microbiome and maintained antibioti...